Emergent BioSolutions M&A Summary
Emergent BioSolutions has acquired 11 companies. A total of 2 acquisitions came from private equity firms. It has also divested 2 assets.
Emergent BioSolutions’ largest acquisition to date was in 2018, when it acquired Adapt Pharma Operations for $735M. It’s largest disclosed sale occurred in 2025, when it sold Emergent BioSolutions - Baltimore-Bayview Drug Substance Manufacturing Site to Syngene International for $37M. Emergent BioSolutions has acquired in 4 different US states, and 5 countries. The Company’s most targeted sectors include life science (64%) and healthcare services (19%).
M&A Summary
-
M&A Total Activity13
- M&A Buy Activity11
- M&A Sell Activity2
- Total Sectors Invested 3
- Total Countries Invested 5
- M&A Buy/Sell Connections 10
Unlimited Searches
